Diabetes and Neuroaxonal Damage in Parkinson's Disease

Nirosen Vijiaratnam¹, Michael Lawton^{2

3}, Raquel Real^{1

4}, Amanda J Heslegrave^{5

6}, Tong Guo^{5

6}, Dilan Athauda¹, Sonia Gandhi¹, Christine Girges¹, Yoav Ben-Shlomo³, Henrik Zetterberg^{5

6

7

8

9}, Donald G Grosset¹⁰, Huw R Morris^{1

4}, Thomas Foltynie¹; PRoBaND Clinical Consortium

Affiliations

¹ Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
² School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom.
³ Department of Social Medicine, University of Bristol, Bristol, United Kingdom.
⁴ Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, Maryland, USA.
⁵ Dementia Research Institute, University College London, London, United Kingdom.
⁶ Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen, Square, London, United Kingdom.
⁷ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
⁸ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
⁹ Hong Kong Center, for Neurodegenerative Diseases, Hong Kong, People's Republic of China.
¹⁰ Department of Neurology, Southern General Hospital, University of Glasgow and Institute of Neurological Sciences, Glasgow, United Kingdom.

PMID: 35856732
PMCID: PMC9543586
DOI: 10.1002/mds.29067

Comment

Diabetes and Neuroaxonal Damage in Parkinson's Disease

Nirosen Vijiaratnam et al. Mov Disord. 2022 Jul.

. 2022 Jul;37(7):1568-1569.

doi: 10.1002/mds.29067.

Authors

Affiliations

¹ Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
² School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom.
³ Department of Social Medicine, University of Bristol, Bristol, United Kingdom.
⁴ Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, Maryland, USA.
⁵ Dementia Research Institute, University College London, London, United Kingdom.
⁶ Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen, Square, London, United Kingdom.
⁷ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
⁸ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
⁹ Hong Kong Center, for Neurodegenerative Diseases, Hong Kong, People's Republic of China.
¹⁰ Department of Neurology, Southern General Hospital, University of Glasgow and Institute of Neurological Sciences, Glasgow, United Kingdom.

PMID: 35856732
PMCID: PMC9543586
DOI: 10.1002/mds.29067

No abstract available

PubMed Disclaimer

Comment in

Reply to: "Diabetes and Neuroaxonal Damage in Parkinson's Disease".
Buhmann C, Pötter-Nerger M, Schulz R, Gerloff C, Kuhle J, Choe CU. Buhmann C, et al. Mov Disord. 2022 Jul;37(7):1569-1570. doi: 10.1002/mds.29064. Mov Disord. 2022. PMID: 35856728 No abstract available.

Comment on

Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study).
Uyar M, Lezius S, Buhmann C, Pötter-Nerger M, Schulz R, Meier S, Gerloff C, Kuhle J, Choe CU. Uyar M, et al. Mov Disord. 2022 Jun;37(6):1299-1304. doi: 10.1002/mds.29009. Epub 2022 Apr 6. Mov Disord. 2022. PMID: 35384057

References

1. Uyar M, Lezius S, Buhmann C, et al. Diabetes, glycated haemoglobin (HbA1C), and neuroaxonal damage in Parkinson's disease (MARK‐PD study). Mov Disord 2022;37(6):1299–1304. 10.1002/mds.29009 - DOI - PubMed
1. Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 2019;90:870–881. - PubMed
1. Athauda D, Evans J, Wernick A, et al. The impact of type 2 diabetes in Parkinson's disease. In submission. Mov Disord 2022; in press. - PMC - PubMed
1. Vijiaratnam N, Lawton M, Heselgrave A, et al. Combining biomarkers for prognostic modelling of Parkinson's disease. J Neurol Neurosurg Psychiatry Epub ahead of print 2022;0:1–9. 10.1136/jnnp-2021-328365 - DOI - PMC - PubMed
1. Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: a new target for disease modification? Prog Neurobiol 2016;145‐146:98–120. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Diabetes and Neuroaxonal Damage in Parkinson's Disease

Affiliations

Diabetes and Neuroaxonal Damage in Parkinson's Disease

Authors

Affiliations

Comment in

Comment on

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical